Connecting the Dots: Diabetes, CKD, and CVD Pathways-Understanding the Interplay between T2D, CKD, and CVD

Video Transcription

Video Summary

In the American Association of Clinical Endocrinology Learning Module titled "Connecting the Dots," Dr. Joe Alloy outlines the complex interplay between type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disease pathways. Sponsored by an Abbott Diabetes Care grant, this module includes contributions from various experts. The session aims to explain the relationships between insulin resistance, CKD, and cardiovascular disease, focusing on early detection and guideline-based treatment options. Key therapeutic options include lifestyle changes and medications such as GLP-1 receptor agonists and SGLT2 inhibitors. Dr. Alloy emphasizes the importance of multidisciplinary care, considering 1 in 10 Americans are affected by diabetes, a primary cause of CKD and a major contributor to cardiovascular complications. With an eye on prevention, the module stresses early intervention and risk stratification using tools like risk calculators. He also suggests incorporating digital health technologies for patient engagement and continuous monitoring.

Keywords

type 2 diabetes

chronic kidney disease

cardiovascular disease

GLP-1 receptor agonists

SGLT2 inhibitors

multidisciplinary care